[go: up one dir, main page]

AU2001268055A1 - Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist - Google Patents

Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist

Info

Publication number
AU2001268055A1
AU2001268055A1 AU2001268055A AU6805501A AU2001268055A1 AU 2001268055 A1 AU2001268055 A1 AU 2001268055A1 AU 2001268055 A AU2001268055 A AU 2001268055A AU 6805501 A AU6805501 A AU 6805501A AU 2001268055 A1 AU2001268055 A1 AU 2001268055A1
Authority
AU
Australia
Prior art keywords
antipsychotic
combination
muscarinic agonist
treating psychoses
psychoses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001268055A
Inventor
Franklin Porter Bymaster
Harlan Edgar Shannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001268055A1 publication Critical patent/AU2001268055A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001268055A 2000-06-30 2001-06-18 Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist Abandoned AU2001268055A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21551600P 2000-06-30 2000-06-30
US60/215,516 2000-06-30
PCT/US2001/014863 WO2002003684A2 (en) 2000-06-30 2001-06-18 Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist

Publications (1)

Publication Number Publication Date
AU2001268055A1 true AU2001268055A1 (en) 2002-01-14

Family

ID=22803282

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001268055A Abandoned AU2001268055A1 (en) 2000-06-30 2001-06-18 Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist

Country Status (5)

Country Link
EP (1) EP1316203A2 (en)
JP (1) JP2004502655A (en)
AU (1) AU2001268055A1 (en)
CA (1) CA2411386A1 (en)
WO (1) WO2002003684A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0428170D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Mono and Combination Therapy
GB0428180D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Combination therapy
AU2006282896A1 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
WO2011011060A1 (en) * 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
JP6440625B2 (en) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー Methods and compositions for treating schizophrenia
ES2811088T3 (en) 2014-04-23 2021-03-10 Takeda Pharmaceuticals Co Isoindolin-1-one derivatives as activity of the positive allosteric modulator of the muscarinic cholinergic M1 receptor for the treatment of Alzheimer's disease
UA121503C2 (en) 2015-06-26 2020-06-10 Такеда Фармасьютікал Компані Лімітед 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
WO2017069173A1 (en) 2015-10-20 2017-04-27 武田薬品工業株式会社 Heterocyclic compound
JP7096441B2 (en) 2018-09-28 2022-07-05 カルナ セラピューティックス，インコーポレイテッド Compositions and Methods for Treating Disorders Ameliorated by Muscarinic Receptor Activation
EP4091607A1 (en) * 2021-05-18 2022-11-23 Karuna Therapeutics, Inc. Methods for treating central nervous system disorders with muscarinic receptor activator xanomeline and antipsychotics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses

Also Published As

Publication number Publication date
EP1316203A2 (en) 2003-06-04
WO2002003684A3 (en) 2003-03-13
CA2411386A1 (en) 2002-01-10
JP2004502655A (en) 2004-01-29
WO2002003684A2 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
AU2001266293A1 (en) Intravesicular device
AU2001295596A1 (en) Machine tool
AU2001243326A1 (en) Hand tool
AU5919001A (en) Muscarinic agonists
AU2001266955A1 (en) Policy generator tool
AU2001290616A1 (en) A method for identifying polymorphisms
AU2001259287A1 (en) Personal tool carrying device
AU2002254381A1 (en) Key cutting machine and method
AU2002235224A1 (en) Muscarinic antagonists
AU2002249885A1 (en) Delta agonist analgesics
AU2001232919A1 (en) Banding machine
AU2001247695A1 (en) Hand tool
AU1845301A (en) Internet tool
AU2001268055A1 (en) Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
AU2001276269A1 (en) Tool and associated fixing device
AU2003290104A1 (en) Clamping chuck and key rod therefor
AU2001276354A1 (en) Hetaryl-substituted heterocycles
AU3046401A (en) Countersinking tool for fast-exchange chucks
AU6901201A (en) Tube-filling machine
AU3546200A (en) A method for mobile text entry
AUPR006600A0 (en) Dispensing machine and method
AU2001262371A1 (en) Device for bundling particularly logging waste
AU2000266040A1 (en) Processing tool
AU5262201A (en) Spindle unit and cutting machine with spindle unit
AU5257300A (en) Holder for a key or similar